Placeholder Banner

2016 Snapshot: BIO’s Top Five Health Blogs

December 21, 2016
There was no shortage of health hot topics this year, but as 2016 comes to a close, we wanted to highlight our most read stories. In chronological order, here are this year’s top five favorite health blogs:

  1. BIO Releases Largest Study Ever on Clinical Development Success Rates - Conducted in partnership with Amplion and Biomedtracker, this study generated the most comprehensive analysis, to date, of biopharmaceutical R&D success. Study author and BIO’s Senior Director of Industry Research, David Thomas, CFA stated that by “combining Amplion’s biomarker database with Biomedtracker’s clinical transition records we were able to, for the first time, quantify the benefit of using selection biomarkers in drug development.” In June, Thomas discussed the report – including a rare disease section – during his session at the 2016 BIO International Convention.


  1. Imagine How Much Faster We Could Address Emerging Infections Like Zika and Dengue If We Worked Even Better Together - Nicholas Jackson, VP, Head of Global Research at Sanofi Pasteur wrote a guest blog focusing on the importance of collaboration. With urgent public health needs from unpredictable diseases - like Zika and dengue - Jackson urges for open communication between all players in the vaccine ecosystem. The life-saving benefit if a devastating disease can be controlled in record time would be felt globally. It is this fundamental commitment to collaborate throughout vaccine development which Jackson suggests will win the race against emerging infections.


  1. Bloomberg Caught Spreading Another Inaccurate “False Alarm” About Drug Prices – As BIO’s President & CEO, Jim Greenwood shared his thoughts when Bloomberg’s drug pricing report failed to accurately represent our industry by positioning guesstimates as “proof,” focusing on the small percent of successes, and most of all, ignoring the many, many failures in biopharmaceuticals that need to be taken into account. “But despite failures and uncertainty in commercial success, we continue to invest,” because as Greenwood continuous to reminds us, we will keep going even when faced with stories that get the all the facts wrong because “saving lives is what we do and who we are.”


  1. PhRMA & BIO release joint principles on communications with health care professionals and payers – Co-written by Jeffrey Francer of PhRMA and Deborah Shelton of BIO, the Principles on Responsible Sharing of Truthful and Non-Misleading Information about Medicines with Health Care Professionals and Payers was jointly released to promote greater communication among all stakeholders about the safe and effective use of medicines. ”Removing current regulatory barriers, and clarifying the ability of companies to share truthful and non-misleading information about medicines, is essential to our collective ability to realize the full potential of 21st century medicines helping to ensure that patients are able to get the right medicines at the right time for them,” Francer and Shelton conclude.


  1. All Pharma Wants to Be “Patient-Centric” – What Does That Really Mean? – In November, BIO held their 5th annual Patient and Health Advocacy Summit. Liz Lewis, Chief Counsel and Head of Patient Advocacy at Takeda Oncology was the first in a series of patient-focused guest blogs. Lewis shares how the recent pharmaceutical industry buzzword “patient-centricity” is actually a meaningful concept that Takeda Oncology is committed to. At Takeda Oncology, aspiring to cure cancer calls for patient engagement at all levels - discovery, development, and delivery of medicines. Lewis concludes that truly addressing patients’ needs and “having a full understanding of the patient’s journey is what challenges Takeda Oncology to bring better medicines to market."

Subscribe to our e-newsletter and never miss a story in 2017.